The pharmaceutical and bio industries' offensive toward the obesity treatment market is getting stronger day by day. It is making all-out efforts to judge obesity as a second "endocrine" market such as diabetes. Domestic pharmaceutical companies are also continuing to move beyond Saxenda and Qsymia, which are active in the domestic obesity treatment market. As it is related to other endocrine markets such as diabetes, pharmaceutical companies are more actively courting endocrine physicians who directly prescribe it, judging it as a market that can never be missed.

According to IQVIA, a drug research institute on the 13th, Saxenda, and Qsymia are still active amid the growth of the obesity treatment mark